[Prevalence and drug tolerance of mycoplasma in patients with urogenital inflammation].
OBJECTIVE
To observe the prevalence and drug tolerance of mycoplasma(Ureaplasma urealyticum and Mycoplasma hominis) in patients with urogenital inflammation.


METHODS
Three thousand and fifty-five patients with urogenital inflammation such as non-gonococcal urethritis(NGU), chronic prostatitis or pelvic inflammation from 1999 to 2003 were included. The results of mycoplasma culture and drug sensitivity test were analyzed.


RESULTS
A total of 992(32.5%) cases were mycoplasma positive in the 3,055 patients, and there was no significant difference in the yearly positive percentage in the 5 years (P < 0.05). Among them, 701(70.7%) were infected with Ureaplasma urealyticum, 44(4.4%) with Mycoplasma hominis, and 247(24.9%) with both Ureaplasma urealyticum and Mycoplasma hominis, the Ureaplasma urealyticum infection rate being much higher than that of Mycoplasma hominis and mixed infection (P < 0.01). The high colony counting(> or = 10(4) cfu/ml) in Ureaplasma urealyticum infection patients accounted for 76.7%, while Mycoplasma hominis infection represented only 18.2%. The results of drug tolerance test showed a higher sensitivity to doxycycline, pristinamycin, josamycin and tetracycline (94.3%, 96.6%, 86.5% and 97.4% respectively), and a lower sensitivity to erythromycin and ofloxacin (54.8% and 29.4% respectively).


CONCLUSIONS
Ureaplasma urealyticum and Mycoplasma hominis should be detected simultaneously and the drug tolerance test is needed for the selection of appropriate antibiotics.
Yan
Zi-He
ZH
Department of Laboratory Science, Wuxi Second People's Hospital, Wuxi, Jiangsu 214002, China.
Zhou
Min
M
Zhang
Wen
W
Zhang
De-Lin
DL
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009175:Mycoplasma Infections / Q000453:epidemiology* / Q000382:microbiology; D019535:Mycoplasma hominis / Q000187:drug effects / Q000302:isolation & purification*; D000292:Pelvic Inflammatory Disease / Q000453:epidemiology* / Q000382:microbiology; D015995:Prevalence; D011472:Prostatitis / Q000453:epidemiology* / Q000382:microbiology; D016990:Ureaplasma urealyticum / Q000187:drug effects / Q000302:isolation & purification*; D014526:Urethritis / Q000453:epidemiology* / Q000382:microbiology